Half-year report · HY
2413.TEDINET S100X3FS
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥170.9bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥284.9bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥124.8bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥36.0bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥29.0bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥36.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥64.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥29.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥22.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥40.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥17.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥25.3bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥19.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥612.4bn | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥581.7bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥491.5bn | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥188.7bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥168.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥423.7bn | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥412.8bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥364.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥366.7bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥387.3bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥378.4bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥349.5bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥133.8bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥134.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥148.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥149.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥36.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥51.7bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥23.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥15.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥39.1bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥11.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥22.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥27.2bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥12.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥33.47 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥59.62 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥25.47 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥33.46 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥59.6 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥25.4 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 63.2% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.1% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.1% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 57
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥2.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥2.2bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥804m |
| Career Solutionreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥13.2bn |
| Career Solutionreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥13.1bn |
| Career Solutionreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥38m |
| Career Solutionreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.3bn |
| Evidence Solutionreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥12.2bn |
| Evidence Solutionreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥12.1bn |
| Evidence Solutionreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥85m |
| Evidence Solutionreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥2.3bn |
| Medical Platformreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥52.0bn |
| Medical Platformreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥49.9bn |
| Medical Platformreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2.0bn |
| Medical Platformreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥17.9bn |
| Overseasreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥41.1bn |
| Overseasreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥41.1bn |
| Overseasreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥5m |
| Overseasreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥8.9bn |
| Patient Solutionreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥27.4bn |
| Patient Solutionreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥27.4bn |
| Patient Solutionreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.1bn |
| Site Solutionreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥26.3bn |
| Site Solutionreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥26.3bn |
| Site Solutionreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3m |
| Site Solutionreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.7bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥172.0bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥169.9bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2.2bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥36.2bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥1.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥1.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.7bn |
| Career Solutionreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥11.6bn |
| Career Solutionreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥11.6bn |
| Career Solutionreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥18m |
| Career Solutionreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.1bn |
| Evidence Solutionreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥11.9bn |
| Evidence Solutionreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥11.8bn |
| Evidence Solutionreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥100m |
| Evidence Solutionreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.9bn |
| Medical Platformreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥42.5bn |
| Medical Platformreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥40.7bn |
| Medical Platformreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.7bn |
| Medical Platformreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥14.6bn |
| Overseasreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥38.0bn |
| Overseasreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥38.0bn |
| Overseasreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥28m |
| Overseasreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥6.6bn |
| Site Solutionreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥21.6bn |
| Site Solutionreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥21.6bn |
| Site Solutionreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6m |
| Site Solutionreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥125.6bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥123.7bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.9bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥30.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 668
| Item | Context | Value | Unit |
|---|---|---|---|
| Depreciation and amortization operating expenses IFRS | Prior1InterimDuration_jpcrp040300-ssr_E05425-000OverseasReportableSegmentMember | 1995000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1InterimDuration_ReportableSegmentsMember | 5135000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1InterimDuration_jpcrp040300-ssr_E05425-000OtherEmergingBusinessMember | 0 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1InterimDuration | 5135000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E05425-000MedicalPlatformReportableSegmentMember | 49943000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E05425-000EvidenceSolutionReportableSegmentMember | 12095000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E05425-000CareerSolutionReportableSegmentMember | 13137000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E05425-000SiteSolutionReportableSegmentMember | 26288000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E05425-000PatientSolutionReportableSegmentMember | 27352000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E05425-000OverseasReportableSegmentMember | 41058000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_ReportableSegmentsMember | 169873000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E05425-000OtherEmergingBusinessMember | 1012000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | InterimDuration | 170885000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000MedicalPlatformReportableSegmentMember | 2034000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000EvidenceSolutionReportableSegmentMember | 85000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000CareerSolutionReportableSegmentMember | 38000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000SiteSolutionReportableSegmentMember | 3000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000PatientSolutionReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000OverseasReportableSegmentMember | 5000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_ReportableSegmentsMember | 2165000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000OtherEmergingBusinessMember | 51000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_ReconcilingItemsMember | -2216000000 | JPY |
| Intersegment revenue IFRS | InterimDuration | － | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000MedicalPlatformReportableSegmentMember | 51977000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000EvidenceSolutionReportableSegmentMember | 12180000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000CareerSolutionReportableSegmentMember | 13175000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000SiteSolutionReportableSegmentMember | 26291000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000PatientSolutionReportableSegmentMember | 27352000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000OverseasReportableSegmentMember | 41063000000 | JPY |
| Revenue IFRS | InterimDuration_ReportableSegmentsMember | 172038000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E05425-000OtherEmergingBusinessMember | 1064000000 | JPY |
| Revenue IFRS | InterimDuration_ReconcilingItemsMember | -2216000000 | JPY |
| Revenue IFRS | InterimDuration | 170885000000 | JPY |
| Operating profit loss IFRS | InterimDuration_jpcrp040300-ssr_E05425-000MedicalPlatformReportableSegmentMember | 17870000000 | JPY |
| Operating profit loss IFRS | InterimDuration_jpcrp040300-ssr_E05425-000EvidenceSolutionReportableSegmentMember | 2331000000 | JPY |
| Operating profit loss IFRS | InterimDuration_jpcrp040300-ssr_E05425-000CareerSolutionReportableSegmentMember | 4343000000 | JPY |
| Operating profit loss IFRS | InterimDuration_jpcrp040300-ssr_E05425-000SiteSolutionReportableSegmentMember | 1694000000 | JPY |
| Operating profit loss IFRS | InterimDuration_jpcrp040300-ssr_E05425-000PatientSolutionReportableSegmentMember | 1054000000 | JPY |
| Operating profit loss IFRS | InterimDuration_jpcrp040300-ssr_E05425-000OverseasReportableSegmentMember | 8925000000 | JPY |
| Operating profit loss IFRS | InterimDuration_ReportableSegmentsMember | 36217000000 | JPY |
| Operating profit loss IFRS | InterimDuration_jpcrp040300-ssr_E05425-000OtherEmergingBusinessMember | 578000000 | JPY |
| Operating profit loss IFRS | InterimDuration_ReconcilingItemsMember | -804000000 | JPY |
| Operating profit loss IFRS | InterimDuration | 35992000000 | JPY |
| Finance income and expenses net IFRS | InterimDuration | 689000000 | JPY |
| Profit loss before tax IFRS | InterimDuration | 36681000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_jpcrp040300-ssr_E05425-000MedicalPlatformReportableSegmentMember | 2399000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_jpcrp040300-ssr_E05425-000EvidenceSolutionReportableSegmentMember | 275000000 | JPY |
| Depreciation and amortization operating expenses IFRS | InterimDuration_jpcrp040300-ssr_E05425-000CareerSolutionReportableSegmentMember | 196000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |